Uncategorized
Wegovy and Eating Disorders — Safety & Contraindications
Wegovy is contraindicated in patients with active eating disorders or recent history due to risks of malnutrition, electrolyte imbalance, and
Wegovy Body Dysmorphia — Real Risk or Overblown Concern?
Wegovy body dysmorphia risk exists but affects fewer than 8% of users. Learn the warning signs, who’s most vulnerable, and how to mitigate psychological
Wegovy Binge Eating — Does It Stop Food Compulsions?
Wegovy reduces binge eating episodes by 50-60% in clinical trials through slowed gastric emptying and central appetite suppression — mechanism explained.
Wegovy 1 Month Weight Loss — What to Expect in 30 Days
Most patients lose 4–6 pounds in the first month on Wegovy — here’s the mechanism behind early results and what actually drives meaningful loss.
Wegovy PCOS Weight Loss — Evidence & Medical Protocol
Wegovy reduces insulin resistance and androgen levels in PCOS patients, delivering 15–20% body weight reduction in clinical trials—here’s the protocol.
Wegovy Perimenopause — Weight Loss During Hormonal Shifts
Wegovy during perimenopause addresses hormonal weight gain through GLP-1 receptor agonism that counteracts estrogen-driven metabolic shifts and insulin
Wegovy and Cushing’s — Risks, Contraindications, Safety
Wegovy is not recommended for active Cushing’s syndrome due to cortisol-driven weight gain and metabolic dysfunction that oppose GLP-1 therapy mechanisms.
Wegovy Compounded Same as Brand? Key Differences Explained
Compounded semaglutide contains the same active molecule as Wegovy but differs in FDA approval status, pricing, and manufacturing oversight—here’s what
Wegovy and Hashimoto’s — Safe Use for Thyroid Patients
Wegovy is generally safe for Hashimoto’s patients with stable thyroid function, though TSH monitoring and dose adjustments may be needed alongside GLP-1
